New cancer clinical trial: Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Published on: February 08, 2019 at 10:30PM

• Tweet
• Share
• Share
• Share
• Share